Abstract
Subtle cognitive changes in preclinical Alzheimer’s disease (AD) are difficult to detect using traditional pen-and-paper neuropsychological assessments. Remote and unsupervised digital assessments can improve scalability, measurement reliability, and ecological validity, enabling the detection and monitoring of subtle cognitive change. Here, we evaluate such tools deployed in preclinical AD samples, defined as cognitively unimpaired individuals with abnormal levels of amyloid-β (Aβ), or Aβ and tau.
In this scoping review, we screened 1,680 unique reports for studies using remote and unsupervised cognitive assessment tools in preclinical AD samples; 23 tools were found. We describe each tool’s usability, validity, and reported metrics of reliability.
Construct and criterion validity according to associations with established neuropsychological assessments and measures of Aβ and tau are reported.
With this review, we aim to present a necessary update to a rapidly evolving field, following a previous review by Öhman and colleagues (2021; Alzheimers Dement. Diagn. Assess. Dis. Monit) and addressing the open questions of feasibility and reliability of remote testing in the target population. We discuss future directions for using remote and unsupervised digital cognitive assessments in preclinical AD and how such tools may be used for longitudinal monitoring of cognitive function, scalable case finding, and individualized prognostics in both clinical trials and healthcare contexts.
Competing Interest Statement
SEP and FÖ have nothing to declare. JH is a paid consultant for Eisai, AlzPath, Prothena. AK is an employee of ki:elements. KVP has served as a paid consultant for Novoic, Prothena, and Biogen and is on the advisory board for Cogstate. MS has served on advisory boards for Roche and Novo Nordisk, received speaker honoraria from Bioarctic, Eisai, Genentech, Lilly, Novo Nordisk and Roche and receives research support (to the institution) from Alzpath, Bioarctic, Novo Nordisk and Roche (outside scope of submitted work); he is a co-founder and shareholder of Centile Bioscience and serves as Associate Editor with Alzheimer’s Research & Therapy. DB is co-founder and shareholder of neotiv GmbH.
Funding Statement
This work was supported by the NIH/NIA (1R01AG084017-01A1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No data were produced in the preparation of this manuscript.
